BioNTech SE
BNTX
Positions held
Your positionsBNTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- BioNTech SE is positioned in the biotechnology sector, which is experiencing rapid growth due to increasing demand for innovative therapies and vaccines.
- In 2023, BioNTech reported a revenue of $3.819 billion, with a profit margin of 24.4%.
- The company has a strong gross margin of 84.3%, indicating efficient production and high profitability.
- The biotechnology industry faces intense competition, which can impact BioNTech's market share and pricing power.
- In Q2 2026, BioNTech's revenue dropped to $105.6 million, a decline of 11% from the previous quarter.
- The company's operating margin was severely negative at -888.9% in Q2 2026, highlighting significant operational challenges.
Fundamentals
| Market cap | $23.13B | Enterprise value | $9.98B | Trailing P/E | — | Forward P/E | -16.99 |
| PEG | 0.05 | Price / book | 1.16 | Beta | 1.25 | Dividend yield | 0.00% |
| Revenue growth | -59.5% | Earnings growth | — | Gross margin | 76.6% | Operating margin | -8.1% |
| Profit margin | -63.6% | ROE | -9.3% | ROA | -5.4% | Debt / equity | 0.02 |
| Current ratio | 7.85 | Free cash flow | -$249.56M | Analyst recommendation | buy | Mean target | $116.54 |
| 52w high | $124.00 | 52w low | $79.52 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $106M | $118M | $907M | $1.5B | $261M | — |
| Op margin | -888.9% | -568.3% | -30.9% | 43.1% | -181.0% | — |
| Net income | -$821M | -$532M | -$305M | -$28.7M | -$387M | — |
| Gross margin | 8.1% | 39.5% | 63.3% | 90.2% | 70.7% | — |
| Gross profit | $8.6M | $46.7M | $574M | $1.4B | $184M | — |
| Operating income | -$939M | -$671M | -$281M | $654M | -$472M | — |
- Revenue -11% vs prior quarter ($106M vs $118M).
- Gross margin 8.1% (was 39.5% prior quarter).
- Operating margin compressed to -888.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.9B | $2.8B | $3.8B | $17.3B | — |
| Op margin | -22.3% | -25.8% | 22.9% | 71.1% | — |
| Net income | -$1.1B | -$665M | $930M | $9.4B | — |
| Gross margin | 77.6% | 80.3% | 84.3% | 82.7% | — |
| Gross profit | $2.2B | $2.2B | $3.2B | $14.3B | — |
| Operating income | -$641M | -$709M | $876M | $12.3B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?
2026-10-06 · Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?
2026-10-05 · Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
2026-10-01 · Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
2026-09-30 · Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
2026-09-27 · How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment Story
2026-09-24 · Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
2026-09-23 · Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
2026-09-22 · Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
2026-09-21 · Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.
2026-09-21 · Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
2026-09-17 · Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Price (daily)
Full chart · RSI · MACD · patterns